GNCA Genocea Biosciences Inc.

0.55
-0.01  -2%
Previous Close 0.56
Open 0.57
Price To Book 7.88
Market Cap 47756900
Shares 86,625,975
Volume 159,730
Short Ratio
Av. Daily Volume 220,419

SEC filingsSee all SEC filings

  1. 8-K - Current report 181232257
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181154233
  3. 8-K - Current report 181152078
  4. 8-K - Current report 181102357
  5. 8-K - Current report 181083559

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Announced September 25, 2017 that development will be ceased.
GEN-003
Genital herpes
Topline data did not meet endpoints - September 2015
GEN-004
Universal vaccine candidate against pneumococcus
Phase 1/2 initial data due 1H 2019.
GEN-009 vaccine
Various cancers

Latest News

  1. Read This Before Selling Genocea Biosciences, Inc. (NASDAQ:GNCA) Shares
  2. Genocea Appoints Girish Aakalu, Ph.D., Chief Business Officer
  3. Detailed Research: Economic Perspectives on Genocea Biosciences, Big Lots, SemGroup, Conn's, Mimecast, and Neos Therapeutics — What Drives Growth in Today's Competitive Landscape
  4. Genocea To Host a Key Opinion Leader Event November 26th on Latest Advances in Personalized Cancer Immunotherapies
  5. Edited Transcript of GNCA earnings conference call or presentation 1-Nov-18 1:00pm GMT
  6. Genocea Unveils Possible Mechanism for Tumor Resistance to Immunotherapy at Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting
  7. Genocea Biosciences: 3Q Earnings Snapshot
  8. Genocea Reports Third Quarter 2018 Financial and Operating Results
  9. Genocea to Host Third Quarter 2018 Financial Results Conference Call & Webcast on November 1, 2018 at 9:00 a.m. ET
  10. Do Institutions Own Shares In Genocea Biosciences Inc (NASDAQ:GNCA)?
  11. Analysis: Positioning to Benefit within Genocea Biosciences, Retail Properties of America, Hawkins, QUANTENNA COMMS, Hillenbrand, and Herman Miller — Research Highlights Growth, Revenue, and Consolidated Results
  12. Genocea Announces Upcoming Presentations at SITC 2018
  13. Genocea Strengthens Leadership Team: Thomas Davis, M.D. Appointed Chief Medical Officer; Derek Meisner, J.D. Joins as General Counsel
  14. Genocea to Present at Two October Investor Conferences
  15. Genocea Biosciences Sees Hammer Chart Pattern: Time to Buy?
  16. Edited Transcript of GNCA earnings conference call or presentation 2-Aug-18 1:00pm GMT

SEC Filings

  1. 8-K - Current report 181232257
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181154233
  3. 8-K - Current report 181152078
  4. 8-K - Current report 181102357
  5. 8-K - Current report 181083559
  6. CT ORDER - Confidential treatment order 181010970
  7. S-8 - Securities to be offered to employees in employee benefit plans 18998940
  8. 10-Q - Quarterly report [Sections 13 or 15(d)] 18992920
  9. 8-K - Current report 18986748
  10. 8-K - Current report 18917670